Swiss drugmaker Roche has big ambitions beyond treating cancer, where it is already global market leader, and believes it has a winner in a new multiple sclerosis drug.
While the market for multiple sclerosis (MS) treatments is relatively crowded, Roche thinks its drug ocrelizumab, for which clinical data will be unveiled next month, can grab share by offering top-of-the-range potency with minimal side effects.
Hey, check out all the research scientist jobs. Post your resume today!
